BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
BCL2/BCL2L1 ratio elevation	Multiple Myeloma	BCL2/BCL2L1 ratio elevation	Multiple Myeloma	venetoclax + cobimetinib Sensitive: C3 – Early Trials venetoclax + cobimetinib Sensitive : C3	venetoclax + cobimetinib Sensitive: C3 – Early Trials venetoclax + cobimetinib Sensitive : C3
BCL2/BCL2L1 ratio elevation	Multiple Myeloma	BCL2/BCL2L1 ratio elevation	Multiple Myeloma	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3

BCL2/BCL2L1 ratio elevation

Associations